InvestorsHub Logo
Followers 85
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: stoneroad post# 204625

Saturday, 01/31/2015 4:06:05 PM

Saturday, January 31, 2015 4:06:05 PM

Post# of 346385
stoneroad, you need "ideas" and talk about "ideas" and imagine if you had such a company with paradigm shift ideas. Would you want employees that talk about paradigm shifting ideas that intervene with the progress that delays shareholder value ? There is turnover in every industry and here is the most important fact of them all:

If you have read the employee profiles of many of the Peregrine employees of the past which are publicly available on linkedin

-vs-

the current employee profiles on linked and you can easily conclude that they are more qualified, and shall we say more deserving and respect Peregrine's paradigm shifting "ideas" to the point where you should be pleased that Peregrine has attracted more qualified individuals as the anti-PS platform advances.

So a mute point but since you have not done your research on current employees vs former employees, I wouldn't worry one tear about it.


"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News